Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2022

06.05.2022 | original report

High mortality in patients with active malignancy and severe COVID-19

Results from an Austrian multicenter registry during the first period of the COVID-19 pandemic

verfasst von: Simon Udovica, Nino Müser, Agnes Pechlaner, Andreas Reichinger, Christoph Aichinger, Kathrin Strasser-Weippl, Holger Rumpold, Andreas Petzer, Ewald Wöll, Wolfgang Hilbe, Ercan Müldür

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Various registries of patients with cancer and coronavirus disease 2019 (COVID-19) emerged over the last few months and patients with cancer are reported to be at increased risk for severe outcome of COVID-19. Yet, many studies lack a direct control group and include patients with different baseline parameters. Here we report data for patients with active malignancy who were hospitalized for severe COVID-19 and a control group hospitalized with severe COVID-19, but not diagnosed with ongoing malignant disease. Moreover, we incorporate the prognostic 4C Mortality Score which estimates in-hospital mortality for COVID-19 patients.

Methods

In all, 245 patients hospitalized with severe COVID-19 between March 2020 and March 2021 were included in the analysis. Among those, 89 patients were diagnosed with active malignancy. Primary endpoint was COVID-19-associated mortality.

Results

COVID-19-associated mortality was significantly higher in cancer patients than in the control group (46.1 vs. 27.6%, odds ratio [OR] 2.56, p < 0.001). In multivariable analysis, diagnosis of active malignancy (OR 4.59) and poor ECOG status ≥ 3 (OR 6.56) were the strongest predictors of COVID-19-related death. The prognostic 4C Mortality Score correctly predicted mortality in the control group (occurred: 27.6%, vs. estimated: 27.3%, p > 0.999), but significantly underestimated COVID-19-related mortality in cancer patients (occurred: 46.1% vs. estimated: 32.2%, p = 0.003).

Conclusion

Active malignancy was associated with high mortality in patients with severe COVID-19 during the first period of the COVID-19 pandemic. The mortality rate was underestimated by the 4C Mortality Score.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
8.
Zurück zum Zitat Palmieri C, et al. 1670O Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium. Ann Oncol. 2020;31:992. CrossRef Palmieri C, et al. 1670O Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium. Ann Oncol. 2020;31:992. CrossRef
9.
Zurück zum Zitat de Joode K, et al. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer. 2020;141:171–84. CrossRef de Joode K, et al. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. Eur J Cancer. 2020;141:171–84. CrossRef
10.
Zurück zum Zitat Rüthrich MM, et al. COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry. Ann Hematol. 2021;100:383–93. CrossRef Rüthrich MM, et al. COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry. Ann Hematol. 2021;100:383–93. CrossRef
11.
Zurück zum Zitat Lee AJX, Purshouse K. COVID-19 and cancer registries: learning from the first peak of the SARS-CoV‑2 pandemic. Br J Cancer. 2021;124(11):1777–84. CrossRef Lee AJX, Purshouse K. COVID-19 and cancer registries: learning from the first peak of the SARS-CoV‑2 pandemic. Br J Cancer. 2021;124(11):1777–84. CrossRef
14.
Zurück zum Zitat Gupta A, et al. Early treatment for Covid-19 with SARS-coV‑2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941–50. CrossRef Gupta A, et al. Early treatment for Covid-19 with SARS-coV‑2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385:1941–50. CrossRef
15.
Zurück zum Zitat Kalil AC, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795–807. CrossRef Kalil AC, et al. Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384:795–807. CrossRef
Metadaten
Titel
High mortality in patients with active malignancy and severe COVID-19
Results from an Austrian multicenter registry during the first period of the COVID-19 pandemic
verfasst von
Simon Udovica
Nino Müser
Agnes Pechlaner
Andreas Reichinger
Christoph Aichinger
Kathrin Strasser-Weippl
Holger Rumpold
Andreas Petzer
Ewald Wöll
Wolfgang Hilbe
Ercan Müldür
Publikationsdatum
06.05.2022
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00814-9